- 双特异性抗体工程 -
Exciting progress is being made in engineering for more targeted bispecific therapeutics that have optimal stability and half-life, and proven functionality. Balancing the affinity of the two arms of the bispecific, especially for CD3 targeting products, is seen as a common challenge and efforts are clearly underway to overcome this for enhanced targeting and minimal toxicity. Engineering Bispecifics will present novel approaches to optimize the product and address the challenges.
FOCUS ON T-CELL ENGAGERS FOR POTENCY
KEYNOTE PRESENTATION: Novel T Cell Engagers for Targeted Recruitment of Effector Cells to Tumors
Yoram Reiter, PhD, Head, Molecular Immunology, Technion-Israel Institute of Technology
Design of T Cell-Dependent Bispecific Antibodies with Optimal Relative Target Affinities
Danielle Mandikian, PhD, Associate Scientist, Genentech, Inc.
Fc ENGINEERING FOR ENHANCED PRODUCT PROPERTIES, AND FOR BRAIN DELIVERY
Glyco-Optimization of Antibodies Targeting Immune Checkpoint Molecules: Case Studies of an Agonist and an Antagonist
Christoph Goletz, PhD, Associate Director, Preclinical Pharmacology & Cancer Immunology, Glycotope GmbH
Development of a Novel Fc Heterodimerization Technology
Fabian Richter, PhD, Post-Doc, Biomedical Engineering, Cell Biology and Immunology, University of Stuttgart
Creation of Fcab Bispecifics (Fc with Antigen Binding) with Unique Properties for Immuno-Oncology
Jose Munoz Olaya, PhD, Principal Scientist, F-star
Antibody Transport Vehicle (ATV): A Novel Brain Delivery Platform
Mark S. Dennis, PhD, Fellow, Denali Therapeutics
NOVEL TECHNOLOGIES FOR FASTER DISCOVERY AND SCREENING, AND FOR TARGETING, POTENCY AND LOW RISK OF TOX
Creating a Novel T-Cell Engaging Bispecific Antibody Platform: Fine Tuning Anti-Tumor Activity with Sequence-Based Discovery and Machine Learning
Nathan Trinklein, PhD, Vice President, Teneobio
Case Studies on How Digital and Automated Solutions Transform the Discovery and Development of Next Generation Antibodies
Martin Bader, PhD, Head, Biochemical and Analytical Research, Roche
A Discovery Engine for Therapeutic Bispecific Antibodies Based on Transgenic Mice, Common Light Chains and Human IgG Molecules.
John de Kruif, PhD, CTO, Merus
Redefinition of ErbB2/3 Tumor Targeting: How to Design Truly Potent Bispecific and Biparatopic Agents
Rastislav Tamaskovic, PhD, Head, TC Facility, Senior Scientist, Biochemistry, University of Zurich
BISPECIFIC CYTOKINES TO ENHANCE TARGETING AND HALF-LIFE AND DECREASE TOXICITY
Development of Novel Interleukin2 Variants for Immunotherapy of Cancer and Autoimmune Diseases
Ekkehard Moessner, PhD, Head, Protein Engineering, Large Molecules Research, Roche Innovation Center Zurich
BI AND MULTI-SPECIFIC ANTIBODY FRAGMENTS AND PEPTIDES
Developing Humabody VH Therapeutics for Immuno-Oncology
James Legg, PhD, Vice President, R&D, Crescendo Biologics Ltd.
Turning Affibody Molecules into Efficient Peptide Binders by Dimerization
John Lofblom, PhD, Associate Professor, Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm